Filociclovir

Filociclovir
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name 2-amino-9-[(Z)-[2,2-bis(hydroxymethyl)cyclopropylidene]methyl]-1H-purin-6-one;
CAS Number	632325-71-4;
PubChem CID	135409256;
ChemSpider	2276035;
UNII	EAO0TD9B13;
KEGG	D10632;
CompTox Dashboard (EPA)	DTXSID10212612 ;
Chemical and physical data
Formula	C11H13N5O3
Molar mass	263.25 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1/C(=C/N2C=NC3=C2N=C(NC3=O)N)/C1(CO)CO;
	InChI InChI=1S/C11H13N5O3/c12-10-14-8-7(9(19)15-10)13-5-16(8)2-6-1-11(6,3-17)4-18/h2,5,17-18H,1,3-4H2,(H3,12,14,15,19)/b6-2-; Key:KMUNHOKTIVSFRA-KXFIGUGUSA-N;

Filociclovir (cyclopropavir, MBX-400) is an antiviral drug which was developed for the treatment of cytomegalovirus infection and also shows some activity against other double-stranded DNA viruses. It has reached Phase II human clinical trials.[1][2][3]

References

Chemaly RF, Hill JA, Voigt S, Peggs KS (March 2019). "In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review". Antiviral Research. 163: 50–58. doi:10.1016/j.antiviral.2019.01.008. PMID 30677427.
Rouphael NG, Hurwitz SJ, Hart M, Beck A, Anderson EJ, Deye G, et al. (September 2019). "Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers". Antimicrobial Agents and Chemotherapy. 63 (9): e00717–19. doi:10.1128/AAC.00717-19. PMC 6709474. PMID 31285228.
Hussein IT, Brooks J, Bowlin TL (January 2020). "The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease". Antiviral Research. 176: 104710. doi:10.1016/j.antiviral.2020.104710. PMID 31940473.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Chemaly RF, Hill JA, Voigt S, Peggs KS (March 2019). "In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review". Antiviral Research. 163: 50–58. doi:10.1016/j.antiviral.2019.01.008. PMID 30677427.

[2] Rouphael NG, Hurwitz SJ, Hart M, Beck A, Anderson EJ, Deye G, et al. (September 2019). "Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers". Antimicrobial Agents and Chemotherapy. 63 (9): e00717–19. doi:10.1128/AAC.00717-19. PMC 6709474. PMID 31285228.

[3] Hussein IT, Brooks J, Bowlin TL (January 2020). "The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease". Antiviral Research. 176: 104710. doi:10.1016/j.antiviral.2020.104710. PMID 31940473.